Abstract: An exhaled breath condensate (EBC) collection device comprising two adjacent parts foldable together and apart from each other, a condensation zone to condense exhaled breath from a subject, the condensation zone being a third part provided between the two adjacent parts and connectable to cooling means arranged in each of the two parts being in cooling relationship with the condensation zone. There is also provided a method for detecting antigens or antibodies to the antigens, the method comprising collecting EBC from a subject using the EBC collection device, performing immunochromatographic testing (ICT) of the collected exhaled breath condensate, and interpreting the immunochromatographic testing results as follows: if the immunochromatographic testing results are positive, the antigens or antibodies to the antigens are detected, or if the immunochromatographic testing results are negative, the antigens or antibodies to the antigens are not detected.

Abstract: A method for reducing motility and number of L. donovani cells, said method comprising contacting the L. donovani cells with an effective amount of a composition, the composition comprising a combination of metronidazole and itraconazole, wherein the effective amount is sufficient to reduce motility of the L. donovani cells.

Abstract: A composition for reducing miR-3120 expression in a cell or tissue of a subject comprises at least one oil or extract selected from a group comprising an orange, frankincense and cannabis oil or extract. A method for reducing miR-3120 expression in a cell or tissue of a subject comprises administering to the subject a composition comprising at least one oil or extract selected from the group comprising an orange, frankincense and cannabis oil or extract.

Abstract: A method for reducing motility and number of L. donovani cells, said method comprising contacting the L. donovani cells with an effective amount of a composition, the composition comprising a combination of metronidazole and itraconazole, wherein the effective amount is sufficient to reduce motility of the L. donovani cells.

Abstract: Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric.

Abstract: Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric.

Abstract: We propose here that endogenous stem/progenitor cells of the developing or adult nervous system be genetically modified in situ, to express therapeutically advantageous gene products. Furthermore, we propose here that endogenous or other exogenous stem cells or their progeny be genetically modified when appropriate to express advantageous gene products (and/or modified through culture techniques), and that, if exogenously derived, they be transplanted into the ventricular system of the patient nervous system, the germinal zone of the ventricular system, into postmitotic regions of the CNS or other organs.